Orexin receptors in the CA1 region of hippocampus modulate the stress-induced antinociceptive responses in an animal model of persistent inflammatory pain

Peptides. 2022 Jan:147:170679. doi: 10.1016/j.peptides.2021.170679. Epub 2021 Oct 27.

Abstract

Stress activates multiple neural pathways and neurotransmitters that often suppress pain perception, the phenomenon called stress-induced analgesia (SIA). Orexin neurons from the lateral hypothalamus project to entire brain structures such as the hippocampus. The present study examined this hypothesis that orexinergic receptors in the CA1 region of the hippocampus may play a modulatory role in the development of SIA in formalin test as an animal model of persistent inflammatory pain. One hundred-two adult male Wistar rats were administered with intra-CA1 orexin-1 receptor (OX1r) antagonist, SB334867, at the doses of 3, 10, 30, and 100 nmol or TCS OX2 29 as orexin-2 receptor (OX2r) antagonist at the doses of 1, 3, 10, and 30 nmol. Five min later, rats were exposed to forced swim stress (FSS) for a 6-min period. Then, pain-related behaviors induced by formalin injection were measured at the 5-min blocks during a 60-min period of formalin test. The current study indicated that solely stress exposure elicits antinociception in the early and late phases of the formalin test. The FSS-induced analgesia was prevented by intra-CA1 administration of SB334867 or TCS OX2 29 during either phase of the formalin test. Moreover, the contribution of the OX2r in the mediation of analgesic effect of stress was more prominent than that of the OX1r during both phases of the formalin test. It is suggested that OX1r and OX2r in the CA1 region of the hippocampus are involved in stress-induced analgesia in the animal model of persistent inflammatory pain.

Keywords: CA1 region of hippocampus; Forced swim stress; Formalin test; Orexinergic system; Pain; Rat; Stress; Stress-induced analgesia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Combined Chemotherapy Protocols
  • Benzoxazoles / administration & dosage
  • Benzoxazoles / pharmacology
  • CA1 Region, Hippocampal / drug effects
  • CA1 Region, Hippocampal / physiology*
  • Cyclophosphamide
  • Disease Models, Animal
  • Doxorubicin
  • Etoposide
  • Inflammation / etiology
  • Isoquinolines / administration & dosage
  • Isoquinolines / pharmacology
  • Male
  • Microinjections
  • Naphthyridines / administration & dosage
  • Naphthyridines / pharmacology
  • Orexin Receptor Antagonists / administration & dosage
  • Orexin Receptor Antagonists / pharmacology
  • Orexin Receptors / metabolism*
  • Pain / drug therapy
  • Pain / etiology*
  • Pain Measurement
  • Prednisone
  • Pyridines / administration & dosage
  • Pyridines / pharmacology
  • Rats
  • Rats, Wistar
  • Stress, Psychological / etiology*
  • Urea / administration & dosage
  • Urea / analogs & derivatives
  • Urea / pharmacology
  • Vincristine

Substances

  • 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea
  • 1-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3,3-dimethyl-2-((4-pyridinylmethyl)amino)-1-butanone
  • Benzoxazoles
  • Hcrtr1 protein, rat
  • Hcrtr2 protein, rat
  • Isoquinolines
  • Naphthyridines
  • Orexin Receptor Antagonists
  • Orexin Receptors
  • Pyridines
  • Vincristine
  • Etoposide
  • Doxorubicin
  • Cyclophosphamide
  • Urea
  • Prednisone

Supplementary concepts

  • EPOCH protocol